Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Stopped early
Conditions studied: Lung Diseases, Interstitial, Pulmonary Fibrosis
In brief
The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better predictor of disease progression. ILD's are a group of chronic, progressive lung diseases. The most common ILD is idiopathic pulmonary fibrosis (IPF). Metabolomics provides a "snapshot" in time of all metabolites present in a biological sample. The imaging procedure should take approximately 20 minutes. All study related collections of samples will be done in a single visit if possible. There are no direct benefits to participants. This is not a treatment study.
Key facts
- Study ID
- NCT04119115
- Run by
- Corewell Health East
- People needed
- 28
- Starts
- 2021-09-30
- Expected to finish
- 2022-10-20
- Last updated by the study team
- 2023-05-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Patients greater than 18 years of age
- Patients with a PFT-Pulmonary function test </=3 month plus seven days
- Patients with idiopathic pulmonary fibrosis (IPF), or
- Patients with interstitial lung disease (ILD) other than IPF, or
- Patients with chronic obstructive pulmonary disease COPD/emphysema based on Principal's Investigator's assessment/review, or
- Control subject, someone without a diagnosis of above and deemed and "healthy control" by the PI.
- COPD/emphysema and control subjects will be age matched +/-10 years to the ILD subjects.
You may not qualify if…
- Patients less than 18 years of age
- Patients with active malignancy in past one year, except for basal and squamous cell skin cancer
- Patients without a PFT-Pulmonary function test </=3 month plus seven days
- Pregnant females
- Cognitive impairment and unable to follow directions, per PI discretion
Where it is running
- Beaumont Health — Royal Oak, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.